Vascular diseases are the leading cause of death in Spain. Hypercholesterolemia is not only
a cardiovascular risk factor, but also underlies the etiopathogenesis of atherosclerosis …

Background Rosuvastatin (Crestor), a new, highly efficacious statin, has demonstrated dose-
dependent low-density lipoprotein cholesterol (LDL-C) reductions of up to 65% in a dose …

BACKGROUND: Lowering low-density lipoprotein cholesterol (LDL-C) levels reduces the
risk of coronary heart disease. The introduction of a highly efficacious new statin …

Introduction: Reducing low-density lipoprotein cholesterol (LDL-C) with lipid-lowering
therapies has been associated with a decrease in the frequency of cardiovascular events …

BACKGROUND:: The majority of clinical trials investigating the clinical benefits of lipid-
lowering therapies (LLTs) have focused on North American or western and nothern …

BACKGROUND:: Rosuvastatin is a new statin indicated to reduce elevated levels of total
cholesterol, low-density lipoprotein cholesterol (LDL-C), and triglycerides and to increase …

Background The VOYAGER meta-analysis reported on the low-density lipoprotein
cholesterol (LDL-C)-lowering effect of commonly used statins in Caucasian subjects. As …

Objective: This article reviewed the collective evidence from routine clinical practice to
summarize the existing literature on the effectiveness of rosuvastatin in treating …

Aim: Achievement of target lipid levels is a one of the most important part of the
cardiovascular risk reduction to which an obvious way is to switch from current drug to a …

Many patients at high cardiovascular risk still fail to achieve recommended LDL-C goals.
Showing evidence of a difference between two statins at the same dose can significantly …